Patents by Inventor Thomas D. Yager

Thomas D. Yager has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220283153
    Abstract: The disclosure provides a panel of biomarkers that individually or in combination can indicate the presence of sepsis as distinguishable from other non-infection related inflammatory conditions. The disclosed biomarkers and related reagents and kits provide strategies for detecting, treating, and monitoring sepsis in subjects. In aspect, the disclosure provides a method for detecting sepsis, comprising contacting a biological sample obtained from the subject with an affinity reagent that specifically binds to one or more of the disclosed novel biomarkers, and detecting differential expression of the one or more biomarkers by detecting binding of the affinity reagent to the biomarker. The method can incorporate use of additional known biomarkers. The method can further comprise treating a subject determined to have sepsis. In some embodiments, the subject is a human subject less than 20 years old.
    Type: Application
    Filed: August 4, 2020
    Publication date: September 8, 2022
    Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    Inventors: Thomas D. Yager, Dayle L. Sampson, Silvia Cermelli, Therese Seldon, Krupa Navalkar, Adrian Piliponsky
  • Patent number: 7655443
    Abstract: Simultaneous sequencing and quantitation of a nucleic acid analyte in a sample using the same reagents for both assays is achieved by processing a sample containing, or suspected of containing the nucleic acid analyte of interest using a single set of reagents through a plurality of thermocycles to obtain a mixture of labeled polynucleotides which are used for the determination of both sequence information about the target nucleic acid and the amount of target nucleic acid present in the sample. The fragments are separated on the basis of size, for example by electrophoresis, and the label associated with the separated fragments is detected. The positions of the separated nucleic acid fragments are evaluated to obtain information about the sequence of the target nucleic acid analyte, and the intensity of a signal derived from the label associated with one or more of the separated fragments is evaluated to determine the quantity of the target nucleic acid analyte in the sample.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: February 2, 2010
    Assignee: Siemens Healthcare Diagnostics, Inc.
    Inventors: Thomas D Yager, M Jason August
  • Patent number: 7386399
    Abstract: The present invention is directed to a method for alignment of nucleic acid data traces. The method involves selecting reference alignment points from among internal peaks representing highly conserved bases, preferably consisting of heterogeneous multiplets. The alignment points may also optionally include the primer peak and/or the full-length peak. Reference position numbers are assigned to these alignment points reflecting the known relative position of the alignment point, a sequence position number is assigned to peaks in the data traces so as to maximize assigning the sequence position number and the reference position number to the same base. Optionally, the method may include the step of determining the average peak spacing interval between alignment points and assigning a sequence position number to peaks occurring at the intervals. The data traces are then aligned based on the assigned sequence position numbers.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: June 10, 2008
    Inventors: Alexandre M. Izmailov, Thomas D. Yager
  • Publication number: 20020029969
    Abstract: A microelectrophoresis chip comprises a substrate in which there are formed one or more channels, one channel for each sample to be evaluated. The channels extend for the length of the chip, a distance of generally around 1 cm, and are about 1 to 10 &mgr;m wide and 1 to 10 &mgr;m in depth. The channels are filed with a homogeneous separation matrix which acts as an obstacle to the electrophoretic migration of the charged molecules. Microelectrodes disposed in the channels are used to induce an electric filed within the homogeneous separation medium. When a voltage is applied across two or more of the microelectrodes, the charged molecules are induced to move and separate according to the electric field density, the type of solvent film, and the charge, shape and size of the charged molecule.
    Type: Application
    Filed: July 16, 2001
    Publication date: March 14, 2002
    Inventors: Thomas D. Yager, Paul Waterhouse, Alexandre M. Izmailov, Bruno C. Maruzzo, John K. Stevens, Marina T. Larson
  • Patent number: 6261430
    Abstract: A microelectrophoresis chip comprises a substrate in which there are formed one or more channels, one channel for each sample to be evaluated. The channels extend for the length of the chip, a distance of generally around 1 cm, and are about 1 to 10 &mgr;m wide and 1 to 10 &mgr;m in depth. The channels are filled with a homogeneous separation matrix which acts as an obstacle to the electrophoretic migration of the charged molecules. Microelectrodes disposed in the channels are used to induce an electric filed within the homogeneous separation medium. When a voltage is applied across two or more of the microelectrodes, the charged molecules are induced to move and separate according to the electric field density, the type of solvent film, and the charge, shape and size of the charged molecule.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: July 17, 2001
    Assignee: Visible Genetics Inc.
    Inventors: Thomas D. Yager, Paul Waterhouse, Alexandre M. Izmailov, Bruno C. Maruzzo, John K. Stevens, Marina T. Larson
  • Patent number: 6176990
    Abstract: A microelectrophoresis chip comprises a substrate in which there are formed one or more channels, one channel for each sample to be evaluated. The channels extend for the length of the chip, a distance of generally around 1 cm, and are about 1 to 10 &mgr;m wide and 1 to 10 &mgr;m in depth. The channels are filled with a homogeneous separation matrix which acts as an obstacle to the electrophoretic migration of the charged molecules. Microelectrodes disposed in the channels are used to induce an electric field within the homogeneous separation medium. When a voltage is applied across two or more of the microelectrodes, the charged molecules are induced to move and separate according to the electric field density, the type of solvent film, and the charge, shape and size of the charged molecule.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: January 23, 2001
    Assignee: Visible Genetics Inc.
    Inventors: Thomas D. Yager, Paul Waterhouse, Alexandre M. Izmailov, Bruno C. Maruzzo, John K. Stevens, Marina T. Larson
  • Patent number: 6110339
    Abstract: Separation matrices useful in the formation of solid-state mm- to cm-scale devices for the rapid, high-resolution separation of single-stranded DNA ladder bands generated by the Sanger dideoxy- or Maxam/Gilbert chemical DNA sequencing procedures are formed from a solid support (1) having a plurality of posts (4) disposed on a first major surface thereof to form an obstacle course of posts (4) and pores (5). The posts are arranged in a regular X, Y array and are separated one from another by a distance of 100 nm or less, preferably 10 to 30 nm, and are optionally separated into lanes 2. The separation matrix can be manufactured by first forming a mold, preferably a reusable mold using lithography techniques. The mold is the reverse of the desired pattern of posts and pores of the obstacle course, and is used for casting the obstacle course. The cast obstacle course is then fused to a solid support and separated from the mold.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: August 29, 2000
    Assignee: Visible Genetics Inc.
    Inventors: Thomas D. Yager, Paul Waterhouse, Alexandre M. Izmailov, Bruno Maruzzo, John K. Stevens, Marina T. Larson
  • Patent number: 6025139
    Abstract: A ligase-based assay which relies only upon knowledge of the wild-type sequence of a gene or gene fragment is used to detect all types of mutations, i.e., point mutations, insertions and deletions. The assay makes use of a set of oligonucleotide probes, which may be packaged in kit form, which hybridize in series along the length of the gene. The ligation of the probes together form a ligation product, the size of which is evaluated. When the gene or gene fragment being analyzed corresponds to the normal sequence and thus perfectly matches the probes, all of the probes in the set are ligated together, and the ligation produce has a certain resulting size. When a mutation appears in the gene, the hybridization of the probe overlapping the mutation is impaired, with the result that some or all of the ligation produce is of smaller size. By evaluating the size of the ligation product, both the existence of a mutation and its approx. position can be identified.
    Type: Grant
    Filed: February 23, 1998
    Date of Patent: February 15, 2000
    Assignee: Visible Genetics Inc.
    Inventors: Thomas D. Yager, James M. Dunn
  • Patent number: 5888731
    Abstract: A ligase-based assay which relies only upon knowledge of the wild-type sequence of a gene or gene fragment is used to detect all types of mutations, i.e., point mutations, insertions and deletions. The assay makes use of a set of oligonucleotide probes, which may be packaged in kit form, which hybridize in series along the length of the gene. The ligation of the probes together form a ligation product, the size of which is evaluated. When the gene or gene fragment being analyzed corresponds to the normal sequence and thus perfectly matches the probes, all of the probes in the set are ligated together, and the ligation product has a certain resulting size. When a mutation appears in the gene, the hybridization of the probe overlapping the mutation is impaired, with the result that some or all of the ligation product is of smaller size. By evaluating the size of the ligation product, both the existence of a mutation and its approximate position can be identified.
    Type: Grant
    Filed: January 24, 1996
    Date of Patent: March 30, 1999
    Assignee: Visible Genetics Inc.
    Inventors: Thomas D. Yager, James M. Dunn